Reliably optimizing a new treatment in humans is a critical first step in clinical evaluation since choosing a suboptimal dose or schedule may lead to failure in later trials. At the same time if promising preclinical results do not translate into a real treatment advance it is important to determine this quickly and terminate the clinical evaluation process to avoid wasting resources. Bayesian Designs for Phase I–II Clinical Trials describes how phase I–II designs can serve as a bridge or protective barrier between preclinical studies and large confirmatory clinical trials. It illustrates many of the severe drawbacks with conventional methods used for early-phase clinical trials and presents numerous Bayesian designs for human clinical trials of new experimental treatment regimes. Written by research leaders from the University of Texas MD Anderson Cancer Center this book shows how Bayesian designs for early-phase clinical trials can explore refine and optimize new experimental treatments. It emphasizes the importance of basing decisions on both efficacy and toxicity. | Bayesian Designs for Phase I-II Clinical Trials